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Adhemar Longatto Filho3,4,5,7 and Vinicius de Lima Vazquez1,6,7Abstract
Background: Epidemiological studies that describe cancer survival statistics at specific hospitals are scarce. Cancer
registries, which are collections of cancer patient characteristics, treatment and outcome data, help determine
quality of care and treatment indicators.
Methods: This study analysed data from patients treated between 2000 and 2009 at the Hospital de Câncer de
Barretos, a referral cancer hospital in Brazil. The analysis included all cases among the nine most common types of
cancer diagnosed between 2000 and 2009. The main characteristics of the patients, tumours, treatment procedures
and survival were described and discussed. The five-year survival rate of patients with cancer diagnosed between
2000 and 2005 were estimated using Kaplan-Meier methods. Multivariable analysis was performed using Cox
proportional hazards regression.
Results: It was analyzed 42,825 cancer cases relating to the nine primary locations in more frequent at the
institution. Most of the patients were men (52.8%) and over the age of 60 years (65.1%). Approximately 1% of the
treated cancers were not staged, and 0.4% lacked follow-up data. Excluding nonmelanoma skin cancer, the most
common tumours were prostate and breast cancer, which were mainly diagnosed at early stages. Five-year survival
for these cancers were 78.2% and 74.8%, respectively.
Conclusions: During this ten-year period, the Hospital de Câncer de Barretos Registry collected, processed and
analysed data related to all cases treated at the institution, providing relevant information about patient
characteristics and survival.
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Cancer is the principal cause of death in developed coun-
tries and the second leading cause of death in developing
countries. There were an estimated 12.7 million new can-
cer cases and 7.6 million deaths globally in 2008, according
to the International Agency for Research on Cancer (IARC)
[1]. Breast cancer has the highest incidence in women,
while lung cancer in men has the highest mortality. The
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distribution, and reproduction in any mediumInstitute (INCA) estimate that approximately 490,000 new
cancer cases in Brazil were diagnosed in 2011 [2]. The
most common cancers are those that arise in lung, breast,
colon and rectum, stomach, prostate, liver, cervical and
oesophageal tissues. The high incidences, mortality rates,
and prevalence of these common malignancies are asso-
ciated with socioeconomic factors, individual behaviour,
and infectious and microenvironment risk factors. Ap-
proximately 25 million persons worldwide were living with
cancer in 2002 [3].
The idea of creating registries for certain diseases
arose from the need to comprehensively characterize the
diseases in order to help identify their causes and, conse-
quently, the most effective interventions [4]. Informationtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient and tumour characteristics
Primary site Sex Age group Disease stage
Male Female <60 60+ 0 I II III IV
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Nonmelanoma skin 10858 9784 5163 15479 813 17928 1617 261 23
(52.6) (47.4) (25.0) (75.0) (3.9) (86.9) (7.8) (1.3) (0.1)
Prostate 6508 - 1011 5497 0 457 3291 1685 1075
(100.0) (15.5) (84.5) (0.0) (7.0) (50.6) (25.9) (16.5)
Breast 21 5236 3385 1872 450 816 2048 1470 473
(0.4) (99.6) (64.4) (35.6) (8.6) (15.5) (38.9) (28.0) (9.0)
Cervical - 2631 1924 707 1091 413 422 558 147
(100.0) (73.1) (26.9) (41.5) (15.7) (16.0) (21.2) (5.6)
Colorectal 1341 1208 1187 1362 19 417 862 652 599
(52.6) (47.4) (46.6) (53.4) (0.7) (16.4) (33.8) (25.6) (23.5)
Lung 1431 636 757 1310 0 97 52 950 968
(69.2) (30.8) (36.6) (63.4) (0.0) (4.7) (2.5) (46.0) (46.8)
Stomach 1031 436 610 857 9 190 181 345 742
(70.3) (29.7) (41.6) (58.4) (0.6) (13.0) (12.3) (23.5) (50.6)
Oesophagus 737 116 447 406 6 20 195 348 284
(86.4) (13.6) (52.4) (47.6) (0.7) (2.3) (22.9) (40.8) (33.3)
Oral cavity 677 174 456 395 13 113 160 189 376
(79.6) (20.4) (53.6) (46.4) (1.5) (13.3) (18.8) (22.2) (44.2)
Figure 1 Overall survival curves for different types of cancer as estimated using Kaplan-Meier methods.
Carneseca et al. BMC Research Notes 2013, 6:141 Page 2 of 10
http://www.biomedcentral.com/1756-0500/6/141












n (%) n (%) n (%) n (%) n (%)
Nonmelanoma skin 0 673 (82.8) 0 (0.0) 140 (17.2) 0 (0.0) 0 (0.0) 813
I 15349 (85.6) 1 (0.01) 2569 (14.33) 1 (0.01) 8 (0.04) 17928
II 1309 (81.0) 0 (0.0) 307 (19.0) 0 (0.0) 1 (0.1) 1617
III 158 (60.5) 1 (0.4) 98 (37.6) 3 (1.1) 1 (0.4) 261
IV 10 (43.4) 1 (4.4) 11 (47.8) 1 (4.4) 0 (0.0) 23
Prostate I 191 (41.8) 0 (0.0) 206 (45.1) 1 (0.2) 59 (12.9) 457
II 1365 (41.5) 203 (6.2) 1446 (44.0) 8 (0,2) 269 (8.1) 3291
III 223 (13.2) 176 (10.5) 681 (40.4) 15 (0.9) 590 (35.0) 1685
IV 0 (0.0) 61 (5.7) 160 (14.9) 6 (0.5) 848 (78.9) 1075
Breast 0 256 (57.0) 0 (0.0) 132 (29.4) 7 (1.6) 54 (12.0) 449
I 219 (26.8) 193 (23.6) 69 (8.4) 37 (4.5) 299 (36.7) 817
II 446 (21.8) 737 (36.0) 92 (4.5) 52 (2.5) 721 (35.2) 2048
III 119 (8.1) 919 (62.5) 23 (1.5) 26 (1.8) 383 (26.1) 1470
IV 14 (3.0) 232 (49.0) 35 (7.4) 46 (9.7) 146 (30.9) 473
Cervical 0 1072 (98.3) 0 (0.0) 17 (1.5) 0 (0.0) 2 (0.2) 1091
I 187 (45.3) 2 (0.5) 196 (47.4) 26 (6.3) 2 (0.5) 413
II 12 (2.8) 5 (1.2) 161 (38.2) 237 (56.2) 7 (1.6) 422
III 15 (2.7) 11 (1.9) 168 (30.1) 352 (63.1) 12 (2.2) 558
IV 5 (3.4) 8 (5.4) 67 (45.6) 61 (41.5) 6 (4.1) 147
Colorectal 0 18 (94.7) 0 (0.0) 1 (5.3) 0 (0.0) 0 (0.0) 19
I 256 (61.4) 13 (3.1) 31 (7.4) 56 (13.4) 61 (14.7) 417
II 329 (38.2) 208 (24.1) 73 (8.5) 145 (16.8) 107 (12.4) 862
III 160 (24.5) 284 (43.6) 25 (3.8) 92 (14.1) 91 (14.0) 652
IV 93 (15.5) 309 (51.6) 43 (7.2) 118 (19.7) 36 (6.0) 599
Lung I 66 (68.0) 6 (6.2) 18 (18.6) 7 (7.2) 0 (0.0) 97
II 20 (38.5) 14 (26.9) 9 (17.3) 9 (17.3) 0 (0.0) 52
III 36 (3.8) 387 (40.8) 81 (8.5) 423 (44.5) 23 (2.4) 950
IV 20 (2.1) 354 (36.6) 244 (25.2) 320 (33.1) 30 (3.1) 968
Stomach 0 8 (88.9) 0 (0.0) 1 (11.1) 0 (0.0) 0 (0.0) 9
I 178 (93.7) 7 (3.7) 1 (0.5) 0 (0.0) 4 (2.1) 190
II 93 (51.4) 38 (21.0) 23 (12.7) 3 (1.7) 24 (13.2) 181
III 114 (33.0) 86 (24.9) 32 (9.3) 15 (4.3) 98 (28.5) 345
IV 172 (23.2) 370 (49.9) 95 (12.8) 54 (7.3) 51 (6.8) 742
Oesophagus 0 4 (66.7) 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 6
I 14 (70.0) 0 (0.0) 5 (25.0) 1 (5.0) 0 (0.0) 20
II 32 (16.4) 8 (4.1) 97 (49.8) 56 (28.7) 2 (1.0) 195
III 27 (7.8) 22 (6.3) 147 (42.2) 144 (41.4) 8 (2.3) 348
IV 18 (6.3) 54 (19.0) 114 (40.2) 92 (32.4) 6 (2.1) 284
Oral cavity 0 11 (84.6) 0 (0.0) 2 (15.4) 0 (0.0) 0 (0.0) 13
I 82 (72.6) 0 (0.0) 30 (26.5) 1 (0.9) 0 (0.0) 113
II 73 (45.6) 2 (1.3) 69 (43.1) 14 (8.7) 2 (1.3) 160
III 53 (28.1) 8 (4.2) 83 (43.9) 37 (19.6) 8 (4.2) 189
IV 90 (23.9) 25 (6.6) 137 (36.5) 83 (22.1) 41 (10.9) 376
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Prostate 2487 619 78.2
Breast 2158 637 74.8
Cervical 751 300 60.2
Colorectal 1009 526 48.1
Lung 959 790 9.2
Stomach 673 464 28.2
Oesophagus 444 365 8.7
Oral cavity 385 200 45.9
All cases 8871 3901 57.1
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are critical for determining prevention strategies and for
supporting public health initiatives that aim to decrease
the incidence of the disease. Such initiatives illustrate
the usefulness of information from population-based
cancer registries [4]. Most descriptive cancer studies
make use of these sources, rather than using data from
hospital cancer registries. The cancer registries at gen-
eral hospitals or cancer hospitals collect data related to
the diagnosis, treatment and outcome of patients with
malignant tumours. A hospital registry is essential for
assessing the quality of information, which reflects the
quality of the medical care performed in these hospitals.
Careful statistical analysis and interpretation of the data
allow the hospital to monitor treatment effectiveness and
help the professional staff make treatment decisions and
follow-up their cases [4]. Currently, in South America,
most of the hospital data related to patient mortality are
underestimated; survival rates not known. For cancer pa-
tients, this is mainly due to a lack of information, or poor
quality information, regarding patient medical history,
cancer type, cancer staging and place of death. This lack
of accurate and thorough records currently prevents the
comparison of data in different hospital registries [5]. Ac-
cordingly, the main objectives of this study were to cha-
racterize the major cancers treated at the Hospital de
Câncer de Barretos, from 2000 to 2009.
The city of Barretos, where is located the Fundação
Pio XII – Hospital de Câncer de Barretos, is situated on
northern region of the São Paulo State, Brazil. With ap-
proximately 112000 inhabitants [6], its economy is essen-
tially composed of agriculture (primarily, by cane sugar,
oranges and soybeans), trade and services. In addition to
dairy industries, rubber, citrus juices and artefacts, slaugh-
terhouses in the region are important ways to exporting
beef to the domestic and foreign market. This characte-
ristic of the economy is that it gives a characteristic rural
to Barretos, unlike other municipalities upcountry in the
state.
The Hospital de Câncer de Barretos receives cancer
patients from all regions of Brazil, with approximately
1000 medical visits per day. The hospital is currently
recognized as one of the main references for the treat-
ment of cancer in the country, it has also focused in the
last years over the field of research and medical educa-
tion. The data obtained by the institutional Cancer Hos-
pital Registry allowed this study, so that a summary of
the information about the tumor (site and stage at first
examination) and patient survival could be made.
Methods
This retrospective study analysed data retrieved from the
Hospital de Câncer de Barretos Registry. In this Registry,patient medical records are entered into a database
according to a standardized procedure. Personal informa-
tion, such as sex, age group and education level, as well as
tumour characteristics such as site, date of diagnosis, dis-
ease stage and initial treatment, were extracted from the
database and analysed.
The study included all cases among the nine most
common types of malignant tumor diagnosed at the
Hospital de Câncer de Barretos between 2000 and
2009. In addition, we analyzed only the cases effec-
tively treated in the institution and disease staging
classified by TNM. A consent term was assigned by
each patient participating in the study in your admis-
sion at the institution and the study has been ap-
proved by the Research Ethics Committee of Hospital
de Câncer de Barretos.
Initially we conducted a preliminary analysis of all
available variables; subsequently, we determined the five-
year survival for cases diagnosed between 2000 and 2005
using Kaplan-Meyer methods. The survival rates were
estimated in months, and survival was defined as the
period from the date of the first hospital consultation to
the date of death or the date at which information was
last obtained from the patient. For the analysis, the event
of interest was death related to cancer. Cases that were
alive or dead from other causes were censored. It is
understood by death from other causes, death that oc-
curred due to diseases other than cancer such as heart
disease or other medical conditions. Such information
was obtained through direct consultation to the death
certificate or medical records. Multivariable Cox propor-
tional hazards regression models were used to estimate
hazard ratios (HRs) and 95% confidence intervals (CIs)
with adjustment for sex, age group and disease stage.
Possible confounders such as initial treatment were also
included as variable in this analysis [7]. All analyses were
stratified for primary site of cancer. The data were
exported to SPSS for WindowsW v. 17.0 (Inc., Chicago,








value*Male Female <60 60+ I II III IV
Prostate - - - 87.7 76.8 <0.01 96.5 91.6 84.4 36.0 <0.01
Breast 77.8 74.8 0.62 76.5 71.6 0.02 95.2 87.1 58.4 32.1 <0.01
Cervical - - - 63.2 54.4 <0.01 79.7 61.5 38.5 11.2 <0.01
Colorectal 45.4 51.2 0.08 52.2 44.5 0.01 77.1 61.4 46.6 6.3 <0.01
Lung 7.6 12.9 <0.01 10.6 8.3 0.31 44.0 25.4 9.9 1.6 <0.01
Stomach 25.6 34.6 0.03 26.5 29.3 0.54 85.4 47.1 26.8 5.8 <0.01
Oesophagus 7.8 11.8 0.76 7.7 9.6 0.87 62.9 14.2 7.8 0.0 <0.01
Oral cavity 45.5 45.8 0.51 48.4 42.2 0.20 77.9 56.2 50.0 23.1 <0.01
* Log-rank test.
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significance was set at 0.05 for all analyzes.
We used the International Classification of Diseases for
Oncology (ICD-O) [8] for classification and coding of the
topography and histology of the tumours. Tumours were
staged using the TNM Classification of Malignant Tumours
as proposed by the International Union against Cancer
(UICC) [9].Figure 2 Survival curves according to sex as estimated using Kaplan-Results
During the study period from 2000–2009, 67,010 new ana-
lytical cases were registered at the Hospital de Câncer de
Barretos in Brazil. The nine most common types of malig-
nant tumor were nonmelanoma skin cancers, prostate,
breast, cervical, colorectal, lung, stomach, oesophagus and
oral cavity. They were diagnosed in 73.5% of the cases re-
gistered in this period (n = 49,269). Of these, we analyzedMeier methods.
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classification and treated at the institution. These cases in-
cluded 20,642 cases of nonmelanoma skin cancer (48.2%),
6508 cases of prostate cancer (15.2%), 5257 cases of breast
cancer (12.3%), 2631 cases of cervical cancer (6.1%), 2549
cases of colorectal cancer (6.0%), 2067 cases of lung cancer
(4.8%), 1467 cases of stomach cancer (3.4%), 853 cases of
oesophagus cancer (2.0%) and 851 cases of oral cavity tu-
mours (2.0%).
There were more men in the study population (52.8%,
n = 22,604), and more patients were older than 60 years
(65.1%, n = 27,885). Regarding education level, the pa-
tients were predominantly illiterate or had an incom-
plete primary school education. About 30% of patients
lived outside of São Paulo State. However, as patients
residing near Barretos (cities in the São Paulo State),
most patients living far from the institution was diag-
nosed with advanced cancer (49.7% versus 48.6%, ignor-
ing cases of nonmelanoma skin). The distribution of
cases according to primary malignant neoplasm, sex, age
group and clinical stage are shown in Table 1.
The majority of cases of prostate, breast or cervical
cancers were at less advanced stages. In contrast, pa-
tients with lung, stomach, oesophagus and oral cavity tu-
mours generally were more advanced in stage at theFigure 3 Survival curves according to age group as estimated using Ktime of diagnosis. This is reflected in the survival curves
shown in Figure 1.
Regarding the initial treatment, surgery alone was the
most commonly indicated therapy, with the specific
treatment depending on the type of malignant neoplasm
and its clinical stage. Table 2 shows the initial treatments
according to tumour site and clinical stage. The majority
of stages 0–II tumours were primarily treated surgically.
Considering tumours at all sites (but excluding non-
melanoma skin tumours), the survival rate was 57.1% for
cases diagnosed between 2000 and 2005 (Table 3). The
five-year survival rates were also calculated for each of the
eight primary sites (Table 3). These calculations showed
that among the most prevalent malignancies, the usually
screened cancers had the highest survival rates: Prostate,
breast and cervical cancer had survival rates of 78.2%,
74.8% and 60.2%, respectively. In contrast, lung and
oesophagus cancer had five-year survival rates of 9.2% and
8.7%, respectively.
There were no significant differences in survival rates
between men and women for the majority of cancers,
even for breast tumours, which are rare for men (Table 4,
Figure 2). Lung and stomach cancers had lower survival
rates in men than in women (p<0.01 and p=0.03, res-
pectively). For all tumours, except for stomach canceraplan-Meier methods.
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60 years had higher survival rates than those who were
60+ years old (Table 4, Figure 3). Cases with clinical
stage I tumours, including lung tumours, showed the
highest survival rates regardless of other parameters
(Table 4, Figure 4).
The results of the multivariable Cox regression ana-
lyses are shown in Table 5. The regression models pro-
vided results that were similar to those from the
univariate test (Table 5). For prostate, breast, colorectal
and oral cavity, being 60 years old or older was a risk fac-
tor for death. Being female appeared to be a protection
factor for lung cancer. Clinical stage was a risk factor for
death from cancer for all primary tumour sites studied.
Discussion
Cancer registries that are administrated by cancer hospi-
tals have been criticized for the plethora of reporting dif-
ferences that could bias the data reported by these
institutions [5]. Prior to the year 2000, we also found it
difficult to evaluate the mortality rates at the Hospital de
Câncer de Barretos due to differences in the methods
used to report cancer and patient data. We solved this
problem by creating a modern cancer registry based onFigure 4 Survival curves according to clinical stage as estimated usinstandardized data reporting. In addition, our team of
professionals was trained to report complex information
in a standardized, easy-to-understand manner. As a re-
sult, we were able to extract and analyse key information
about cancer survival at our institute.
The Hospital de Câncer de Barretos treats cancer pa-
tients that come from more than 2000 cities in Brazil,
including many from remote regions. The socioeco-
nomic characteristics of patients treated in Barretos are
especially variable as a result of the wide range of risk
factors and cultural norms in different Brazilian popula-
tions. This makes an analysis such as this one particu-
larly interesting but also introduces potential bias. The
data extraction and analysis were done carefully with at-
tention to detail to avoid discrepancies and misinterpre-
tations. We chose to analyse survival by using data
obtained between 2000 to 2009 to ensure that the infor-
mation had been collected and stored according to a
standardized protocol. Our results are robust, describing
the most frequent malignancies we treat at our institu-
tion and highlighting data that may help us understand
the courses of aggressive malignancies.
The high rates of cancer cases treated at the institution
in advanced stage do not necessarily reflect the Braziliang Kaplan-Meier methods.
Table 5 Cox proportional hazards model for cancer-specific mortality
Variable Primary site
Prostate Breast Cervical Colorectal Lung Stomach Oesophagus Oral cavity
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sex
Male - 1.00 - 1.00 1.00 1.00 1.00 1.00
Female - 2.46 (0.61; 9.93) - 0.88 (0.74; 1.05) 0.78 (0.66; 0.91) 0.86 (0.70; 1.06) 1.03 (0.77; 1.38) 1.10 (0.79; 1.55)
Age-group
<60 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
60+ 1.49 (1.13; 1.98) 1.29 (1.10; 1.52) 1.04 (0.81; 1.32) 1.27 (1.07; 1.52) 1.10 (0.95; 1.28) 0.92 (0.75; 1.11) 1.11 (0.900; 1.38) 1.41 (1.06; 1.88)
Stage disease
I 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
II 2.22 (0.71; 6.96) 2.48(1.59; 3.86) 1.99 (1.26; 3.15) 1.94 (1.36; 2.78) 1.59 (0.82; 3.07) 3.60 (2.09; 6.22) 4.98 (1.80; 13.82) 2.10 (1.07; 4.15)
III 3.79 (1.20; 11.90) 8.10 (5.22; 12.59) 4.91 (3.18; 7.57) 3.23 (2.26; 4.63) 2.24 (1.36; 3.68) 6.73 (3.99; 11.35) 7.26 (2.63; 20.07) 3.03 (1.57; 5.86)
IV 20.13 (6.44; 62.94) 18.30 (11.67; 28.71) 10.84 (6.73; 17.47) 13.44 (9.39; 19.24) 4.88 (2.95; 8.06) 15.93 (9.62; 26.37) 12.00 (4.29; 33.56) 6.34 (3.34; 12.02)
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center in the country, where there are many regions with
lack of resources, impeding them to promote the early de-
tection, appropriate diagnostic and treatment to its popula-
tion, making necessary to send this cases to an institution
far from the original area. An additional factor is the
high number of illiterate Brazilians (9.6% according to
the Census of the Brazilian Institute of Geography and
Statistics – IBGE - in 2010) [6] that may lead to low levels
of basic hygiene and health care, reflecting in late diagno-
sis. The high rate of illiterate patients identified at the in-
stitution (22%) can be explained by the fact that the
majority of patients seen at the institution live in small cit-
ies, where in Brazil are higher than the large cities [6]. In
addition, many patients reside in small towns from North-
east and North of the country (15%), regions that still have
significant rates of illiteracy, above the national average.
Cancer aggressiveness and, consequently, mortality
rates are thought to be directly related to Public Health
efforts to detect cancer at early stages [10]. Although the
study does not allow this type of inference, it was noticed
that tumors targets Government prevention programs,
such as the cervix and breast cancer, were the ones that
had more diagnoses at the initial phase of the disease, gi-
ving them a higher probability of a good outcome. This is
reflected in the high number of surgeries performed as
first-line therapy for these types of cancer. Therapeutic
success is in part associated with early cancer detection.
Prevention programmes carried out by the Brazilian
Government are mostly opportunistic and Hospital de
Câncer de Barretos is one of the proponents institutions of
prevention programs for skin cancer [11], cervix, prostate
[12,13] and breast cancer [14] recognized in the country.
The effectiveness of these programs is perceived through
the large number of patients recruited from around the
country that are sent to the institution for clinical and
complementary examination and specialized treatment.
However, this number is low compared to the number of
cases that come for treatment out of prevention programs.
It is expected that in long-term these programs will help
increase the number of cases of cervix, breast and prostate
cancer treated at the institution that have been diagnosed
in the early stages of the disease.
Although the data from a hospital registry does not ne-
cessarily represent the incidence or prevalence of cancer
in a population, in countries where information from
population-based cancer registries are underutilized such
as Brazil and others, these data can help identify emerging
trends, especially in regions where a few large hospitals
treat a high volume of referred patients.
Conclusion
During the ten-year period from 2000–2009, the Hos-
pital de Câncer de Barretos Registry collected, processedand analysed data from all cases treated at the institu-
tion. These data provide relevant information about pa-
tient and disease characteristics and patient survival.
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